Invitae Corp. is acquiring Seattle-based companies YouScript Inc., and Genelex Corp., as well as Belgium's Orbicule BV.

Total consideration for the three transactions is $195 million.

Orbicule, which is doing business as Diploid, is the developer of artificial intelligence software Moon, used to enable clinical diagnosis using whole genome sequencing.

Invitae, a San Francisco-based medical genetics company, acquired Diploid for about $95 million, subject to certain adjustments. The amount comprises $32 million in cash and $63 million in Invitae common stock. The transaction has closed.

Invitae will acquire YouScript, a clinical decision support and analytics platform provider, for about $79.3 million, with $25 million to be paid in cash and $54.3 million in Invitae common stock.

Invitae will acquire pharmacogenetic testing company Genelex for about $20.7 million in Invitae common shares plus additional shares, if certain milestones are met.

The two acquisitions are likely to close in the coming weeks, pending customary closing conditions.

As part of the Diploid deal, Invitae granted restricted stock units worth up to $5 million to certain continuing employees of Diploid. The restricted stock units were granted under Invitae's 2015 stock incentive plan.